Disease Modification in Psoriasis Through Early IL-17 Inhibitor Intervention: A Retrospective Cohort Study

Table 1 presents baseline laboratory parameters stratified by disease duration:USDD: Psoriasis duration≤1 year，LDD1:Psoriasis duration>1 year;SDD:Psoriasis duration≤2 year,LDD2:Psoriasis duration>2 year. Tables 2-3 identify predictors of PASI 100 achievement at 4 and 52 weeks via logistic regression, demonstrating that shorter disease duration significantly increases the likelihood of achieving PASI 100 at both timepoints.

Table 4 compares baseline characteristics and discontinuation rates by recurrence status, showing significantly longer mean disease duration and higher discontinuation rates in the recurrence group. Table 5 establishes predictors of relapse through logistic regression, revealing that each additional year of disease duration increases relapse risk by 3% (OR=1.03, 95%CI=1.007-1.054, p=0.01). Table 6 examines relapse after IL-17A discontinuation in ultra-short disease duration (USDD: Psoriasis duration≤1 year) versus long duration (LDD1:Psoriasis duration>1 year): After adjusting for baseline PASI, BSA, and other confounders, USDD showed 78.8% lower relapse risk (OR=0.212, 95%CI=0.055-0.826, p=0.025).